UroGen Pharma (URGN) Price Target Raised to $50 by Oppenheimer

Oppenheimer has increased the price target of UroGen Pharma (URGN) to $50, driven by positive sales outlook. This adjustment reflects expectations for future revenue growth and potential market performance. The revised target indicates increased confidence in UroGen's business trajectory. This news is significant for investors as it may influence stock performance and investor sentiment toward UroGen Pharma.